[go: up one dir, main page]

ES2186798T3 - Composicion para la absorcion mejorada de medicamentos polares desde el colon. - Google Patents

Composicion para la absorcion mejorada de medicamentos polares desde el colon.

Info

Publication number
ES2186798T3
ES2186798T3 ES96927128T ES96927128T ES2186798T3 ES 2186798 T3 ES2186798 T3 ES 2186798T3 ES 96927128 T ES96927128 T ES 96927128T ES 96927128 T ES96927128 T ES 96927128T ES 2186798 T3 ES2186798 T3 ES 2186798T3
Authority
ES
Spain
Prior art keywords
colon
composition
salt
mixture
dispersing agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96927128T
Other languages
English (en)
Inventor
Peter James Watts
Lisbeth Illum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Kirin Services Ltd
Original Assignee
West Pharmaceutical Services Drug Delivery and Clinical Research Center Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by West Pharmaceutical Services Drug Delivery and Clinical Research Center Ltd filed Critical West Pharmaceutical Services Drug Delivery and Clinical Research Center Ltd
Application granted granted Critical
Publication of ES2186798T3 publication Critical patent/ES2186798T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA INVENCION PROPORCIONA UNA COMPOSICION DE ADMINISTRACION DE FARMACOS PARA ADMINISTRACION COLONICA QUE COMPRENDE UN FARMACO POLAR, UN PROMOTOR DE ABSORCION QUE (A) CONSTA DE UNA MEZCLA DE UN ACIDO GRASO DE 6 A 16 ATOMOS DE CARBONO O UNA SAL DE ESTE Y UN AGENTE DISPERSANTE, O (B) COMPRENDE UNA MEZCLA DE MONO/DIGLICERIDOS DE ACIDOS GRASOS DE CADENA MEDIA Y UN AGENTE DISPERSANTE, Y UN MEDIO ADAPTADO PARA LIBERAR EL FARMACO POLAR Y EL PROMOTOR DE ABSORCION EN EL COLON TRAS SU ADMINISTRACION ORAL. UN ACIDO GRASO PREFERIDO ES EL ACIDO CAPRICO O UNA SAL DE ESTE. LA LIBERACION ESPECIFICA EN EL COLON PUEDE LOGRARSE AL SUMINISTRAR LA COMPOSICION EN UNA CAPSULA, TABLETA O PILDORA REVESTIDAS CON UN MATERIAL QUE SE DISUELVE EN EL INTESTINO DELGADO O SE DEGRADA POR LAS CONDICIONES EXISTENTES EN EL COLON.
ES96927128T 1995-08-08 1996-08-08 Composicion para la absorcion mejorada de medicamentos polares desde el colon. Expired - Lifetime ES2186798T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9516268.1A GB9516268D0 (en) 1995-08-08 1995-08-08 Compositiion for enhanced uptake of polar drugs from the colon

Publications (1)

Publication Number Publication Date
ES2186798T3 true ES2186798T3 (es) 2003-05-16

Family

ID=10778960

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96927128T Expired - Lifetime ES2186798T3 (es) 1995-08-08 1996-08-08 Composicion para la absorcion mejorada de medicamentos polares desde el colon.

Country Status (13)

Country Link
US (1) US6200602B1 (es)
EP (1) EP0843558B1 (es)
JP (1) JPH11510506A (es)
AT (1) ATE227136T1 (es)
AU (1) AU707587B2 (es)
CA (1) CA2227764A1 (es)
DE (1) DE69624711T2 (es)
DK (1) DK0843558T3 (es)
ES (1) ES2186798T3 (es)
GB (1) GB9516268D0 (es)
NO (1) NO980047L (es)
PT (1) PT843558E (es)
WO (1) WO1997005903A2 (es)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5885567A (en) * 1993-10-22 1999-03-23 University Of Connecticut Treatment of infection in fowl by oral administration of avian interferon proteins
GB9700624D0 (en) 1997-01-14 1997-03-05 Danbiosyst Uk Drug delivery composition
CA2294988C (en) 1997-07-01 2015-11-24 Isis Pharmaceuticals Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal
US7153845B2 (en) * 1998-08-25 2006-12-26 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US8765177B2 (en) * 1997-09-12 2014-07-01 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US6423334B1 (en) 1997-10-01 2002-07-23 Elan Corporation, Plc Composition and method for enhancing transport across gastrointestinal tract cell layers
SE9703691D0 (sv) * 1997-10-10 1997-10-10 Astra Ab Pharmaceutical compositions
FR2775188B1 (fr) * 1998-02-23 2001-03-09 Lipha Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption
US6099859A (en) * 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
AU745880B2 (en) * 1998-05-21 2002-04-11 Isis Pharmaceuticals, Inc. Compositions and methods for non-parenteral delivery of oligonucleotides
GB9824604D0 (en) * 1998-11-11 1999-01-06 Hewlett Healthcare Limited Treatment of allergic conditions
WO2000033866A1 (en) * 1998-12-04 2000-06-15 Provalis Uk Limited Pharmaceutical compositions containing insulin
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
US7658938B2 (en) * 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
AU2681300A (en) * 1999-02-22 2000-09-14 Elan Corporation, Plc Solid oral dosage form containing an enhancer
US8119159B2 (en) * 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
SE9901272D0 (sv) * 1999-04-09 1999-04-09 Astra Ab New improved formulation
US7169889B1 (en) 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
YU43702A (sh) * 1999-12-23 2004-11-25 Pfizer Products Inc. Farmaceutske kompozicije koje obezbeđuju povećanje koncentracije leka
CA2337484A1 (en) * 2000-02-18 2001-08-18 Jin-Emon Konishi Fatty acid-containing composition
JP2001240558A (ja) * 2000-02-29 2001-09-04 Nippon Suisan Kaisha Ltd 多価不飽和脂肪酸を経粘膜吸収促進剤として含有する固形製剤。
CN1406131A (zh) * 2000-12-25 2003-03-26 株式会社资生堂 活化交感神经的香料组合物
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6867183B2 (en) * 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
EP1390048A2 (en) * 2001-02-16 2004-02-25 Shimizu Pharmaceutical Co., Ltd. Oral formulations containing mucopolysaccharide for small intestine delivery and their use in the treatment circulatory disorders
WO2002083120A2 (en) * 2001-04-18 2002-10-24 Prometic Biosciences Inc. Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors
WO2002092070A1 (en) * 2001-05-11 2002-11-21 Elan Corporation, Plc Isostearic acid salts as permeation enhancers
WO2002092616A1 (en) 2001-05-11 2002-11-21 Orasense, Ltd. Antisense permeation enhancers
US6713452B2 (en) 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6835802B2 (en) 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6858580B2 (en) 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828305B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7713932B2 (en) 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
EP1401406A2 (en) 2001-07-02 2004-03-31 Merrion Research I Limited Delivery of a bioactive material
IL159578A0 (en) * 2001-07-06 2004-06-01 Geron Corp Messenchymal cells and osteoblasts from human embryonic stem cell
US7312192B2 (en) * 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US7196059B2 (en) * 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7166571B2 (en) * 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6913903B2 (en) 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
AU2002363182A1 (en) * 2001-11-02 2003-05-12 Ribopharma Ag Smad7 inhibitors for the treatment of cns diseases
MY139721A (en) * 2002-04-19 2009-10-30 Cpex Pharmaceuticals Inc Pharmaceutical composition
GB0210397D0 (en) * 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
WO2003105768A2 (en) 2002-06-13 2003-12-24 Nobex Corporation Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
EP1572244A1 (en) * 2002-12-11 2005-09-14 Chong Kun Dang Pharmaceutical Corp. Oral formulations for poorly absorptive hydrophilic drugs
MXPA05008382A (es) 2003-02-07 2005-11-04 Prometic Biosciences Inc Acidos grasos, gliceridos y analogos con longitud de cadena media como estimuladores de eritropoyesis.
ITRM20030149A1 (it) * 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
EP1660047B1 (en) 2003-08-13 2013-11-27 Biocon Limited Micro-particle fatty acid salt solid dosage formulations for therapeutic agents
US20050163841A1 (en) * 2003-10-31 2005-07-28 Wong Patrick S. Compositions and dosage forms for enhanced absorption of 3-amino-n-butyl-phosphinic acid
WO2005089714A1 (ja) * 2004-03-24 2005-09-29 Takeda Pharmaceutical Company Limited エマルション安定化製剤
WO2006097793A2 (en) * 2004-04-15 2006-09-21 Chiasma, Ltd. Compositions capable of facilitating penetration across a biological barrier
US20070219131A1 (en) * 2004-04-15 2007-09-20 Ben-Sasson Shmuel A Compositions capable of facilitating penetration across a biological barrier
US7645460B2 (en) * 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of risedronate
US7645459B2 (en) 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of bisphosphonates
US20080286359A1 (en) * 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
US20080287400A1 (en) * 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
WO2006014673A2 (en) 2004-07-19 2006-02-09 Nobex Corporation Insulin-oligomer conjugates, formulations and uses thereof
US20080214618A1 (en) * 2004-08-23 2008-09-04 Auckland Uniservices Limited Gastric Therapies Amd Compositions Therefor
MY139644A (en) * 2005-02-17 2009-10-30 Palm Nutraceuticals Sdn Bhd Improving the quality of crude oils and fats and recovery of minor components
EA200800974A1 (ru) * 2005-09-29 2008-10-30 Репрос Терапьютикс Инк. Композиции с улучшенной биодоступностью, содержащие стероидное производное и полигликолизированный глицерид
JP5047978B2 (ja) * 2005-10-13 2012-10-10 バイオコン・リミテッド インスリン複合体の調製のための方法
US8920918B2 (en) * 2005-10-31 2014-12-30 Kee Action Sports Technology Holdings, Llc Oil and polyethylene glycol fill material for use in paintball shells
NZ571965A (en) * 2006-03-30 2012-02-24 Engene Inc Chitosan-based nanoparticles and methods for transfecting gut cells in vivo
US7704977B2 (en) * 2006-04-07 2010-04-27 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US20070292512A1 (en) * 2006-06-09 2007-12-20 Merrion Research Ii Limited Solid Oral Dosage Form Containing an Enhancer
UA114700C2 (uk) * 2007-10-16 2017-07-25 Біокон Лімітед Тверда фармацевтична форма для перорального застосування та процес її виготовлення
US20090271021A1 (en) * 2008-04-28 2009-10-29 Popp Shane M Execution system for the monitoring and execution of insulin manufacture
US20090280169A1 (en) * 2008-05-07 2009-11-12 Merrion Research Iii Limited Compositions of peptides and processes of preparation thereof
GB0808537D0 (en) * 2008-05-12 2008-06-18 Archimedes Dev Ltd Compositions
GB2482810A (en) 2008-09-17 2012-02-15 Chiasma Inc Enhanced delivery of exenatide using a medium chain fatty acid and salt thereof
US20100064927A1 (en) * 2008-09-17 2010-03-18 Aldo Perrone Starch-based paintball fill material
AU2015201581B2 (en) * 2008-09-17 2017-03-09 Amryt Endo, Inc. Pharmaceutical Compositions and Related Methods of Delivery
EP2400851A4 (en) * 2009-02-25 2012-09-05 Merrion Res Iii Ltd COMPOSITION AND ACTIVE COMPOSITION OF BISPHOSPHONATES
EP2442821B2 (en) 2009-06-18 2025-02-12 Acerus Pharmaceuticals USA, LLC Safe desmopressin administration
EP2446189A1 (en) 2009-06-25 2012-05-02 Koninklijke Philips Electronics N.V. Heat managing device
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
KR101813728B1 (ko) 2009-07-31 2017-12-29 그뤼넨탈 게엠베하 결정화 방법 및 생체이용률
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US20110142889A1 (en) * 2009-12-16 2011-06-16 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
WO2011084618A2 (en) 2009-12-16 2011-07-14 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
MX2012007806A (es) * 2010-01-12 2012-08-01 Novo Nordisk As Composiciones farmaceuticas para administracion oral de peptidos de insulina.
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
US9089484B2 (en) * 2010-03-26 2015-07-28 Merrion Research Iii Limited Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
WO2012071517A2 (en) 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Novel crystalline forms
JP2014501784A (ja) 2011-01-07 2014-01-23 メリオン・リサーチ・Ｉｉｉ・リミテッド 経口投与用の鉄の医薬組成物
WO2016120378A1 (en) 2015-01-29 2016-08-04 Novo Nordisk A/S Tablets comprising glp-1 agonist and enteric coating
ES3029566T3 (en) 2015-02-03 2025-06-24 Amryt Endo Inc Treating acromegaly with oral octreotide
GB201511284D0 (en) * 2015-06-26 2015-08-12 Univ Witwatersrand Jhb An oral pharmaceutical dosage form for the delivery of a peptide and/or protein
US10195218B2 (en) 2016-05-31 2019-02-05 Grunenthal Gmbh Crystallization method and bioavailability
GB201904767D0 (en) 2019-04-04 2019-05-22 Orexo Ab New pharmaceutical compositions
GB201904771D0 (en) 2019-04-04 2019-05-22 Orexo Ab New pharmaceutical compositions
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods
US11896719B2 (en) 2022-01-24 2024-02-13 Calliditas Therapeutics Ab Pharmaceutical compositions

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8518301D0 (en) 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
NZ228285A (en) 1988-03-11 1991-08-27 Teikoku Seiyaku Kk Pharmaceutical composition comprising a polypeptide and adapted for intravaginal administration
GB8812490D0 (en) 1988-05-26 1988-06-29 Agricultural & Food Res Delayed release formulations
ES2045276T3 (es) 1988-07-21 1994-01-16 Hoffmann La Roche Preparacion de insulina
ZA906186B (en) 1989-09-11 1991-06-26 Hoffmann La Roche Pharmaceutical preparations
GB8926639D0 (en) 1989-11-24 1990-01-17 Agricultural & Food Res Delayed release formulations
BE1003677A3 (nl) * 1990-01-29 1992-05-19 Schacht Etienne Werkwijze voor het bereiden van azobevattende polymeren en het gebruik ervan als geneesmiddelafgiftesystemen.
ES2048133T3 (es) 1990-05-04 2000-01-16 Perio Prod Ltd Sistema de descarga de farmacos para el colon.
IT1255895B (it) 1992-10-20 1995-11-17 Laura Chiodini Composizioni farmaceutiche contenenti una calcitonina
DE69434626D1 (de) * 1993-11-17 2006-04-20 Athena Neurosciences Inc Transparente flüssigkeit zur verabreichung von verkapselten medikamenten
JPH08208510A (ja) 1994-11-03 1996-08-13 F Hoffmann La Roche Ag インターフェロン組成物

Also Published As

Publication number Publication date
GB9516268D0 (en) 1995-10-11
CA2227764A1 (en) 1997-02-20
NO980047D0 (no) 1998-01-06
DE69624711D1 (de) 2002-12-12
PT843558E (pt) 2003-03-31
AU6705996A (en) 1997-03-05
DE69624711T2 (de) 2003-07-24
JPH11510506A (ja) 1999-09-14
AU707587B2 (en) 1999-07-15
ATE227136T1 (de) 2002-11-15
EP0843558B1 (en) 2002-11-06
DK0843558T3 (da) 2003-03-03
NO980047L (no) 1998-01-06
EP0843558A2 (en) 1998-05-27
WO1997005903A2 (en) 1997-02-20
US6200602B1 (en) 2001-03-13
WO1997005903A3 (en) 1997-03-13

Similar Documents

Publication Publication Date Title
ES2186798T3 (es) Composicion para la absorcion mejorada de medicamentos polares desde el colon.
MY102459A (en) Oral sustained release pharmaceutical preparation.
ATE248589T1 (de) Matrix zur gesteuerten freisetzung von arzneistoffen
PT825858E (pt) Capsulas de libertacao dependente do tempo contendo acidos poliinsaturados omega-3 para o tratamento da doenca inflamatoria do intestino
IT1149328B (it) Composizione farmaceutica per la somministrazione per via orale di composti che debbono essere assorbiti nell'intestino crasso
EP0225189A3 (en) Targeted enteral delivery system
RU94045950A (ru) Фармацевтический препарат и способ его приготовления
ES2149979T3 (es) Composicion estabilizada para la administracion oral de peptidos.
WO1995018622A1 (en) Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents
NZ241687A (en) Coated granules in a coated capsule
KR890009376A (ko) 분무 건조된 이부프로펜
CA2065652A1 (en) Controlled release gastroresistant pharmaceutical formulations for oral administration containing bile acids and their salts
KR850700212A (ko) 서방성 약제학적 캼셀제
ATE211649T1 (de) Dosisform mit gesteuerter freigabe für kalium
NZ337418A (en) Paracetamol composition with improved rate of absorption
CA2125281A1 (en) Immediate-effect ibuprofen-containing medicament and its use
AU1879597A (en) Tetraether lipids and liposomes containing said lipids, and use of the same
GB2318056A (en) Composition for enhanced uptake of polar drugs from the colon
CA2681514C (en) Use of a masked or coated copper salt for the treatment of macular degeneration
DE69911224D1 (de) Geschmacksmaskierte kautablette mit sofortiger wirkstofffreisetzung sowie herstellungsverfahren
KR970700505A (ko) 산 활성물질을 갖는 경구투여 형태 및 그의 제조방법(oral dosage form containing colestipol as a carrier and acidic active substances and a process for producing the same)
ATE210428T1 (de) Geschmacksmaskierte wässrige lösungen enthaltend ibuprofen und menthol
KR890001565A (ko) 활성성분으로 3- 벤조일옥시-1,3,5(10)-에스트라트리엔-17-[4-(p-비스(2-클로로에틸) 아미노)페닐)부타노일옥시]아세테이트를 함유하는 주사약
JPS56166116A (en) Carcinostatic agent
GB2405094A (en) Pharmaceutical composition for controlled drug delivery system